MedTrace Logo

Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer

NCT01417806 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2011-08-16

No results posted yet for this study

Summary

The majority of small cell lung cancer(SCLC)(50-100%) express somatostatin receptors(type 1-5) with some small cell lung cancer express more than one subtypes. Stimulation of these SSTR's lead to inhibition of angiogenesis and cell growth. SOM230 also lower levels of IGF which is known to contribute to SCLC proliferation. Topotecan is approved for second line therapy in relapsed small cell lung cancer. We hypothesized that combination of both agents should yield greater antitumor activity.

Conditions

Interventions

DRUG

Topotecan and Pasireotide

Topotecan 1.5mg/m2 dailyx5 days and Pasireotide 60 mg IM every 28 days

Sponsors & Collaborators

  • Novartis Pharmaceuticals

    collaborator INDUSTRY

  • South Florida Veterans Affairs Foundation for Research and Education

    lead FED

Principal Investigators

  • Niramol Savaraj, M.D. · VA.Medical Center Miami, Fl. 33125

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2016-06-30
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01417806 on ClinicalTrials.gov